Table 1.
HBV core antibody-positive (surface antigen negative) rituximab-associated HBV reactivation: case reports
| Author | NHL type | Age/gender | Co-morbidity | Prior immunosuppressive therapy | Concurrent immune suppressants | Time to reactivate from first rituximab | Doses of rituximab | Time to reactivate from last rituximab | Liver outcome | Treatment of reactivation | Death |
| Dervite et al. [18] | FL | 69/M | None | 7 cycles CHEP and IFN, then 6 cycles HDAC (1 year prior) | Steroids for 6 months immediately prior | 7 months | 4 | 6 months | Hepatitis | NR | No |
| Westhoff et al. [16] | DLBCL | 73/M | None | CHOP 3 months prior | None | 3 months | NR | 1 month | Liver failure | Lamivudine | Yes |
| Niscola et al. [30] | CLL | 51/M | None | Fludarabine 34 months prior | None | 26 months | 10 | 1 month | Liver failure | Lamivudine | Yes |
| Sarrecchia et al.[31] | CLL | 53/M | HTN | Fludarabine 2 years prior | None | 4 months | 3 | 1 month | Liver failure | Lamivudine | Yes |
| Law et al [32] | DLBCL | 67/M | None | None | CHOP | 5 months | 8 | 1 month | Liver failure | Lamivudine | Yes |
| Sera et al. [33] | Indolent NHL | 59/M | None | CHOP 3 years prior, Dex and VCR 1 year prior | Etoposide, prednisone | 2 months | 3 | 0 month | Liver failure | Lamivudine | Yes |
| Ozgonenel et al. [34] | DLBCL | 21/M | Evans syndrome | None in 6 years prior | CHOP | 2 months | 3 | 0 month | Liver failure | Lamivudine | Yes |
| Yamagata et al. [35] | DLBCL | 55/M | None | None | CHOP | 6 months | 7 | 1 month | Liver failure | Lamivudine | Yes |
| Colson et al. [36] | DLBCL | 48/M | None | None | CHOP | 4 months | 4 | 1 month | Hepatitis | Entecavir | No |
| Garcia-Rodriguez et al. [21] | FL | 53/F | None | Yes (not stated- third-line therapy) | CHOP | 11 months | 3 | 9 months | Hepatitis | Lamivudine | No |
| Garcia-Rodriguez et al. [21] | DLBCL | 68/F | None | None | CHOP | 17 months | 6 | 12 months | Liver failure | Lamivudine | Yes |
| Miyagawa et al. [37] | DLBCL | 75/M | None | None | CHOP | 10 months | 6 | 6 months | Hepatitis | Lamivudine | No |
| Koo et al. [38] | MCL | 71/M | None | None | CHOP | 15 months | 9 | 0 | Liver failure | NR | NR |
| Northwestern active surveillance, 2007 | DLBCL | 61/M | Prior GIST | None | CHOP and radiation | 5 months | 6 | 1 month | Liver failure (warranting liver transplant) | Adefovir | No |
| Northwestern active surveillance, 2009 | DLCBL | 47/F | None | None | CHOP | 10 months | 6 | 0 months | Hepatitis | Tenofovir | No |
| Taiwan active surveillance, 2009 | DLBCL | 79/F | None | None | CHOP | 6 months | 6 | 2 months | Hepatitis | Telbivudine | No |
NHL, non-Hodgkin's lymphoma; FL, follicular lymphoma; CLL, chronic lymphocytic leukemia; FSGN, focal segmental glomerulonephritis; M, male; F, female; pts, patients; HBV, hepatitis B virus; DLBCL, diffuse large B-cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CHEP, cyclophosphamide doxorubicin, etoposide, prednisone; CP, cyclophosphamide, prednisone; AZA, azathioprine; IFN, interferon; HDAC, high-dose cytarabine; GIST, gastrointestinal stromal tumor; SLL, small lymphocytic lymphoma; NR, not reported; VCR, vincristine; Dex, dexamethasone.